SO
EGRX

STRS Ohio’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

STRS Ohio’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,700
Closed -$45K – 2125
2024
Q1 		$45K Sell
8,700
-500
-5% -$2.74K ﹤0.01% 1774
2023
Q4 		$48K Hold
9,200
– – ﹤0.01% 1783
2023
Q3 		$145K Buy
+9,200
New +$165K ﹤0.01% 1649
2022
Q3 		– Sell
-2,900
Closed -$128K – 2109
2022
Q2 		$128K Sell
2,900
-6,400
-69% -$294K ﹤0.01% 1707
2022
Q1 		$460K Buy
+9,300
New +$446K ﹤0.01% 1472
2020
Q4 		– Sell
-1,600
Closed -$67K – 2307
2020
Q3 		$67K Sell
1,600
-10,600
-87% -$464K ﹤0.01% 1918
2020
Q2 		$585K Buy
12,200
+400
+3% +$20K ﹤0.01% 1195
2020
Q1 		$542K Buy
11,800
+400
+4% +$20.1K ﹤0.01% 1068
2019
Q4 		$684K Sell
11,400
-200
-2% -$11.9K ﹤0.01% 1200
2019
Q3 		$656K Sell
11,600
-800
-6% -$45K ﹤0.01% 1039
2019
Q2 		$690K Buy
12,400
+500
+4% +$26.1K ﹤0.01% 1026
2019
Q1 		$600K Hold
11,900
– – ﹤0.01% 1150
2018
Q4 		$479K Hold
11,900
– – ﹤0.01% 1270
2018
Q3 		$825K Hold
11,900
– – ﹤0.01% 994
2018
Q2 		$900K Buy
11,900
+9,900
+495% +$623K ﹤0.01% 958
2018
Q1 		$105K Sell
2,000
-400
-17% -$23.3K ﹤0.01% 1606
2017
Q4 		$128K Sell
2,400
-10,100
-81% -$562K ﹤0.01% 1573
2017
Q3 		$745K Buy
12,500
+3,200
+34% +$194K ﹤0.01% 1094
2017
Q2 		$733K Buy
9,300
+1,300
+16% +$106K ﹤0.01% 1049
2017
Q1 		$663K Buy
+8,000
New +$595K ﹤0.01% 1160
2016
Q2 		– Sell
-6,100
Closed -$247K – 2029
2016
Q1 		$247K Sell
6,100
-2,300
-27% -$146K ﹤0.01% 1462
2015
Q4 		$744K Sell
8,400
-1,400
-14% -$111K ﹤0.01% 987
2015
Q3 		$725K Hold
9,800
– – ﹤0.01% 1013
2015
Q2 		$792K Buy
+9,800
New +$638K ﹤0.01% 1035

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

STRS Ohio's EGRX Position: Q2 2024 in Review

STRS Ohio sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 8,700 shares — an estimated $45K sold.

STRS Ohio first reported a position in EGRX in Q2 2015 and held it in 24 quarters. The position peaked at $900K in Q2 2018. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

  • STRS Ohio reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • STRS Ohio sold 8,700 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $45K.
  • STRS Ohio first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 24 quarters.
  • STRS Ohio's Eagle Pharmaceuticals, Inc. position peaked at $900K in Q2 2018.
  • 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on STRS Ohio's 13F filing for Q2 2024, filed 5 Aug 2024.